Experts agree that awareness of MASLD/MASH and its risk factors is low among general practitioners and primary care physicians. Similarly, patients lack knowledge and the community is spread across different healthcare settings due to co-morbidities. Both were verified during the two initial patient events in Mainz (November 25th, 2023) and Mannheim (January 13th, 2024) and another in Kaiserslautern (November 9th, 2024).
masld24.info
In addition, a first central online hub was created with masld24.info, which provides short, relevant initial information for high-risk patients and synergistically uses existing patient support infrastructures in the areas of diabetes, obesity and liver. The recently published EASL patient guideline as well as the short version and its translations were used as a reference for the content of the website.
steatose.info
In February 2025, steatose.info, a central information platform on the subject of fatty liver/steatosis, was made public for people at risk and those living with steatosis.
Further patient workshops are being planned, as are collaborations with the obesity community. The Fat (in the) Liver initiative is supported by Echosens, Madrigal Pharmaceuticals and Novo Nordisk.